End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29.55 CNY | +1.69% | +5.20% | +4.23% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its low valuation, with P/E ratio at 5.89 and 5.28 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.23% | 94.71B | - | ||
+3.05% | 95.15B | B | ||
+18.68% | 74.93B | D+ | ||
-20.65% | 77.24B | B+ | ||
+6.69% | 30.04B | B | ||
+18.06% | 27.87B | B | ||
+4.32% | 26.97B | A | ||
-1.21% | 16.99B | C+ | ||
-9.10% | 15.16B | B | ||
+20.70% | 12.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2628 Stock
- 601628 Stock
- Ratings China Life Insurance Company Limited